Essay On Glimepiride

This article discussed a 54-year-old patientspatient diagnosed with type 2 diabetes (T2DM). She was overweight by 225 pounds and had a body mass index of 35.2. She started with Metformin medication with poor control. Within two months, glimepiride was added to the regimen. Six months later Hemoglobinhemoglobin A1C (HA1C) was above 8%. Normal range is less than 6%. Her endocrinologist added Exenatide. One month later, she developed abdominal pain, anorexia, and 20-pound weight loss. Her blood glucose became extremely high. After a few days, she was admitted to the ER with severe abdominal pain and difficulty

The purpose of this study is to minimize the risk of hypoglycemia among the elderly. As people with diabetis age, the physiological changes affect the diabetic. The purpose of this study is to consider whether HbA1 goals can be attained without undue treatment burden and decrease the risk of severe hypoglycemia. Though client teaching and minimizing the risk factors of hypoglycemia can prevent further exacerbation of catastrophic events that could have potential lethal outcomes to an older patient with diabetes. The one patient’s case, Mr. J., an 86 year old man who has had type 2 diabetes for 15 years is a quantitative study that focuses on prevention of hypoglycemia in older adults. Interventions include diet, meal planning, medication, glucose

Diabetes is a growing but preventable health concern in the United States.1 It is a problem in the body where blood glucose levels rise higher than normal.1 According to the facts released by the American Diabetes Association in 2013, 25.8 million Americans (8.3%) have diabetes 2 and approximately 90% of all cases of diabetes worldwide are considered type 2 diabetes.3 Type 2 diabetes is a progressive disease where the body cannot use insulin properly and the patient ends up using an oral hypoglycemic agent.1 One of the many classes of medications to help manage diabetes is sulfonylureas, including glyburide and glipizide. These drugs close K-ATP channels on Beta cell membranes and cause the pancreas to release more insulin to lower blood sugar.4 Both glipizide and glyburide are metabolized in the liver5, have high protein binding5, and can decrease hemoglobin A1c (HbA1c) up to 1%-2%.6 According to the Health Insurance Association of America, health insurance is defined as "coverage that provides for the payments of benefits as a result of sickness or injury".7 Insurance companies always strive to achieve their target glycemic goal via the most effective and cost effective therapeutic strategy.8 A literature search was conducted to find data on the benefits of converting patients from glyburide to glipizide to find out why insurance prefers the switch.

Furthermore, with the pharma logical treatments included in this article for the treatment of Type 2 Diabetes, many individuals will be prevented from developing CVD complications. Studies have shown the importance of patients being compliant with treatment leading to positive health outcomes. With the continued care given to these patients with Type 2 Diabetes many are able to have healthier lifestyles

Diabetes mellitus type 2, hemoglobin A1c has improved. As noted above, her creatinine did go up to high of 1.5. We did hold the dose of her metformin and when her creatinine did get better, we did decide to decrease the dose to 500 mg b.i.d., given that her hemoglobin A1c was excellent at 6.0. I think we are safe to do this. I would rather have her hemoglobin A1c be higher given her renal insufficiency.

of the study is to determine the benefits and safety of the drug called Liraglutide in patients with

PH is a 42-year old, Hispanic man who was diagnosed with Type 2 Diabetes (Non-insulin dependent diabetes) about 2 years ago. He is controlling his diabetes with diet, exercise, and metformin 500mg BID. He has no prior history of cardiovascular disease, or hypertension; however, during his past three doctor’s visits, his blood pressure was noted to be elevated (145/85, 140/90, 140/85). Currently, PH takes metformin 1000mg BID, has no known drug allergies and no medical insurance.

On my last week visit with the client, I was glad and satisfied with the outcome of my teaching with the client about her self-administration of degludec insulin and other medications. The patient reported of remembering to administer subcutaneous insulin in the morning and feel so much better and have more energy when she gets up in the morning and had better result of daily glucose monitoring instead of being so low which causing her to be weak and shaky. The patient reported that she does not feel any shaky or weakness upon waking up in the morning and have more energy playing with her dog and more energy throughout the day. The patient also included in her weekly schedule of going to the community swimming pool 3 times per week and

This study was conducted to compare the pharmacokinetics of test and reference formulations of glimepiride + metformin fixed-dose combination tablets under fasting conditions. 2

When being given any new drug be sure to alert the prescribing doctor to other medications and if you need to ask to have a consultation with a pharmacist who specializes in giving consultations for these types of conditions.

The first line for mild to moderate high blood glucose level is diet and exercise, but Mrs. Anna was prescribed an oral anti-hyperglycemic agent to manage the elevated blood glucose level (McKenna, 2012). Metformin is an oral anti-diabetes medication which is believed to enhance glucose tolerance in patients diagnosed with type 2 DM by reducing equally the intestinal glucose absorption and the hepatic production of glucose, associated with a vast improvement of insulin sensitivity in the body tissues (McKenna, 2012). Metformin was also found to create a pleasant potential effect on lowering fibrinolytic activity as well as decreasing the serum lipid levels. The common side effects of metformin are linked to the gastrointestinal like diarrhea,

There is growing concern that intense glucose lowering or the use of certain agents may be associated with adverse cardiovascular outcomes.

Below are data from a Phase 2, randomised, double-blind, placebo-controlled clinical trials, testing the effectiveness of two doses of a new drug designed to lower glucose concentrations in patients suffering from type 2 diabetes. In each trial, patients with Type 2 diabetes were randomised to receive one of two doses of drug or matching placebo once daily for 10 weeks. Whilst the drug has been well tolerated in earlier testing, it has been noted that higher doses are associated with unwanted side effects such as dizziness and nausea.

Pharmacological interventions used to improve glucose control include both oral glucose lowering agents and injectables including glucose like peptide & insulin. Apart from insulin the choice of available pharmacological interventions to treat diabetics has expanded rapidly over the past decade. Till date, the efficacy & safety of these therapies have not been well documented in people with diabetics & CKD.

The sector of focus to which our product is directed mainly are diabetics. Their current number in Spain exceeds 5,300,000. That is more than 14% of the Spanish population, although 6% still have not been diagnosed. Within this large number there are two large groups, Type 1 and Type 2 diabetics, but all of them are possible clients and/or consumers of glucose, to help them recover from hypoglycemia (episodes of low blood glucose).